“Our ability to perform both healthy volunteer trials as well as specialty trials with fullservices will garner efficiencies and drive quality for our partners” said Amy Young, vice president and general manager at DCR. “As research trends continue to involve patient studies earlier in the trial process, the ability to have real-time access to accurate data from a single organization becomes increasingly important.”
Employing software and fully validated systems, the data management services group demonstrates DCR’s ongoing commitment to offer best-in-class development capabilities. DCR has conducted more than 90 early clinical trials in more than 1,000 patients and healthy normal volunteers since 2009, including specialty populations and first-in-human studies. DCR now operates 122beds across two Phase I units in Minneapolis, Minn. and Denver, Colo.
The data management services team will be led by Michael Kreuter, director of DCR, who is located in Denver.
“Data integrity and patient safety are critical in Phase I clinical trial work,” saidKreuter. “We are building on DCR’s solid track record in those areas with a full range of data services necessary for early clinical work.”
Features of the data services group include:
Programmed systems using guidance from CDISC, ICH and other current guides
Client standards, which can be customized and used for future studies
Delivery of final datasets in industry standards including:
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.